Effect of Glucose Degradation Products (GDP) on Endothelial Dysfunction

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the effects of neutral pH and low glucose degradation product (GDP)-containing peritoneal dialysis fluid (PDF) on systemic inflammation and endothelial dysfunction markers in incident PD patients.

Clinical Trial Description

New peritoneal dialysis fluids (PDF) with neutral pH and low glucose degradation products (GDPs) are used in patients on peritoneal dialysis (PD). Low GDP fluids are reported to be more biocompatible than conventional PDF. Determination of biocompatibility has mainly focused on local peritoneal effects; recently, there has been interest in evaluating the systemic biocompatibility of these fluids.

In recent analyses of two retrospective cohorts of Korean PD patients, significant survival advantage was shown for patients treated with the biocompatible PDF compared to patients treated with conventional PDF. However, the mechanisms of survival advantage with low GPD PDF in these observational studies are difficult to assess. Additionally, it is not clear that new PDFs favorably impact risk markers of cardiovascular disease (CVD).

Epidemiologic studies identified an independent association between inflammation and risk of cardiovascular events and mortality; this association has been confirmed in patients with advanced chronic kidney diseases (CKD).Other evidence showed that clinically overt vascular events are preceded by endothelial dysfunction and increases in circulating markers of endothelial activation, including vascular cellular adhesion molecule (VCAM)-1 and intercellular adhesion molecule (ICAM)-1.Moreover, there is an association between inflammation and elevated levels of soluble VCAM-1 and ICAM-1 in patients with or at risk of atherosclerosis. Elevated levels of soluble adhesion molecules are found in ESRD patients, especially in patients with CVD and malnutrition.

The investigators hypothesized that conventional PDF as well as uremia itself lead to local peritoneal changes such as peritoneal neoangiogenesis and fibrosis, effects related to ultrafiltration failure and subsequently volume overload. In addition, direct effect of GDPs and/or increased systemic levels of AGEs activate endothelial cells and increase levels of vascular adhesion molecules and inflammation. Both local and systemic effects of PDF are possibly associated with increased cardiovascular risks and mortality in PD patients.

This study aims to examine the effects of neutral pH and low GDP-containing PDF on systemic inflammation and endothelial dysfunction in incident PD patients in a randomized, controlled study. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Disorders Associated With Peritoneal Dialysis
Kidney Failure, Chronic
Renal Insufficiency

Clinical Trial Details

NCT number	NCT01315314
Study type	Interventional
Source	Kyungpook National University
Contact
Status	Completed
Phase	Phase 4
Start date	October 2005
Completion date	April 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03246984` - VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ	N/A
Completed	`NCT02922361` - Spending and Outcomes for Complex Medicare Advantage Patients
Completed	`NCT02235571` - iChoose Decision Kidney Aid for End-Stage Renal Disease Patients	N/A
Completed	`NCT01933789` - Improving Communication About Serious Illness	N/A
Completed	`NCT01922843` - A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis	Phase 2
Completed	`NCT01930396` - Use of Tinzaparin for Anticoagulation in Hemodialysis	Phase 4
Not yet recruiting	`NCT01674660` - Factors Associated With Interdialytic Blood Pressure Variability in Maintenance Hemodialysis Patients	N/A
Not yet recruiting	`NCT01157260` - The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease	Phase 4
Completed	`NCT01209403` - Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients	Phase 4
Completed	`NCT00753116` - Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension	Phase 1
Recruiting	`NCT00532688` - N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure	Phase 2/Phase 3
Completed	`NCT00534144` - Comparison Between Effects of Two Iron Preparations on Protein in the Urine	Phase 1
Completed	`NCT00528788` - How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis	Phase 4
Completed	`NCT00382044` - Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients	N/A
Completed	`NCT00226902` - Vascular Reactivity in Kidney Disease Patients	N/A
Recruiting	`NCT00235287` - Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease	Phase 4
Completed	`NCT00224081` - DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)	Phase 4
Completed	`NCT00071214` - Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis	Phase 3
Completed	`NCT00049907` - Cardiac and Renal Disease Study (CARDS)	N/A
Completed	`NCT00006297` - Risk Factors for CV Disease in a Dialysis Cohort	N/A